Want to see NZ:BLT full AI Analyst Report?
Top Page
BLIS Technologies Limited
(BLT)
Select Model
Select Model
Rating:60Neutral
Price Target:
$0.03
Action:N/A
Date:10/05/26
The score is driven primarily by improving financial performance and strong revenue momentum, supported by a conservatively levered balance sheet. The biggest offsets are weakened FY2026 cash flow (negative operating and free cash flow) and compressed margins, while the stock also appears overbought technically and carries a high P/E that increases downside sensitivity if execution slips.
Positive Factors
Revenue and B2B growth
Strong FY26 revenue growth, led by a 22% increase in B2B sales, indicates expanding demand for BLIS ingredients, royalties and private-label offerings. B2B momentum across Asia-Pacific and China can broaden the company’s commercial reach and support recurring partner-led growth.
Negative Factors
Margin compression
The sharp FY26 decline in gross margin and modest EBIT margin show that stronger sales have not yet translated into consistently robust operating profitability. Earnings remain sensitive to product mix and cost changes, which could constrain reinvestment and reduce the durability of reported profit growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and B2B growth
Strong FY26 revenue growth, led by a 22% increase in B2B sales, indicates expanding demand for BLIS ingredients, royalties and private-label offerings. B2B momentum across Asia-Pacific and China can broaden the company’s commercial reach and support recurring partner-led growth.
Read all positive factors
BLIS Technologies Limited (BLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.82M
Dividend YieldN/A
Average Volume (3M)706.14K
Price to Earnings (P/E)54.0
Beta (1Y)0.31
Revenue Growth16.01%
EPS Growth-28.57%
CountryNZ
Employees43
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,279,301,600
10 Day Avg. Volume590,540
30 Day Avg. Volume706,142
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)1.37
Price to Sales (P/S)1.22
P/FCF Ratio-24.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BLIS Technologies Limited Business Overview & Revenue Model
Company Description
BLIS Technologies Limited, together with its subsidiaries, specializes in creating and distributing health-focused products. These offerings are underpinned by unique bacterial strains that exhibit bacteriocin activity. The company prominently fea...
How the Company Makes Money
BLIS Technologies makes money primarily by commercializing its probiotic strains and associated products through a mix of business-to-business (B2B) and business-to-consumer (B2C) channels. Key revenue streams include: (1) Sales of probiotic ingre...
BLIS Technologies Limited Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
82
Very Positive
Cash Flow
44
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.67M | 11.56M | 10.48M | 9.96M | 8.80M |
| Gross Profit | 6.25M | 9.01M | 8.23M | 7.77M | 6.87M |
| EBITDA | 1.08M | 1.49M | 1.25M | -746.00K | -2.02M |
| Net Income | 692.00K | 838.00K | 646.00K | -1.35M | -2.71M |
Balance Sheet | |||||
| Total Assets | 14.97M | 14.30M | 12.93M | 12.81M | 14.14M |
| Cash, Cash Equivalents and Short-Term Investments | 8.51M | 9.73M | 8.60M | 8.35M | 8.59M |
| Total Debt | 439.00K | 589.00K | 389.00K | 619.00K | 754.00K |
| Total Liabilities | 1.93M | 1.97M | 1.45M | 1.97M | 1.99M |
| Stockholders Equity | 13.04M | 12.32M | 11.49M | 10.84M | 12.15M |
Cash Flow | |||||
| Free Cash Flow | -720.00K | 1.31M | 486.00K | 9.00K | -2.57M |
| Operating Cash Flow | -595.00K | 1.79M | 1.05M | 106.00K | -2.31M |
| Investing Cash Flow | 451.00K | -1.68M | -819.00K | -4.10M | -262.00K |
| Financing Cash Flow | -147.00K | -217.00K | -224.00K | -275.00K | 8.92M |
BLIS Technologies Limited Technical Analysis
Positive
―
Price Trends
0.02
Positive
0.02
Positive
0.02
Positive
Market Momentum
<0.01
Negative
74.20
Negative
88.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:BLT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 0.02, equal to the 50-day MA of 0.02, and equal to the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 74.20 is Negative, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:BLT.
BLIS Technologies Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $45.49M | 16.07 | ― | 3.60% | 17.86% | 20.79% | |
63 Neutral | $34.15M | 0.03 | ― | ― | 29.55% | -11.97% | |
60 Neutral | $35.82M | 54.00 | ― | ― | 16.01% | -28.57% | |
56 Neutral | $114.80M | 12.16 | ― | 4.23% | 14.16% | 34.82% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | $12.22M | -2.70 | ― | ― | 70.82% | 41.04% |
* General Sector Average
NZ:BLT
BLIS Technologies Limited
0.03
0.01
80.00%
NZ:VTL
Vital Limited
―
―
―
NZ:PHL
Promisia Healthcare Limited
0.65
0.22
50.00%
NZ:TAH
Third Age Health Services Limited
4.46
0.02
0.50%
NZ:RAD
Radius Residential Care Ltd
0.40
0.07
19.76%
NZ:RUA
Rua Bioscience Ltd.
0.03
>-0.01
-24.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.